MK-2214
2214-004
Phase 2 mab active
Quick answer
MK-2214 for Early Alzheimer's Disease is a Phase 2 program (mab) at Merck KGaA, Darmstadt, Germany with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck KGaA, Darmstadt, Germany
- Indication
- Early Alzheimer's Disease
- Phase
- Phase 2
- Modality
- mab
- Status
- active